Washington, D.C. - On October 13-15, 2017 at The Liaison Capitol Hill, in Washington, D.C., the state representatives of the National Alliance of State Prostate Cancer Coalitions (NASPCC) came together from all over the country for NASPCC’s 13th Annual Meeting. The gathering enjoyed a large turnout and involved a stellar group of sponsors, speakers and panelists bringing attention and focus to Prostate Cancer. The theme for this year’s Annual Meeting was “Share, Learn and Lead”.
Attendees who had recently watched Discovery Channel’s “First in Human” about Phase 1 Clinical Trials taking place in Building 1 at NIH heard from Dr. James Gulley on Immunotherapy and Prostate Cancer, a subject of his work in Building 10. Dr. Ashley Ross from Dallas spoke on “Advances in Prostate Cancer”; Mark Vieth spoke about the CDMRP, an important medical research program of the Dept. of Defense; another topic was the USPSTF’s Guidelines on Prostate Cancer Screening presented by Dr. Michael Zaragoza. Panel topics ranged from “Advanced Prostate Cancer” to “Genomic Testing” to “Meet the States” to “New Products and Advances Benefiting Prostate Cancer Patients”. Andrew Chesler of CancerCare spoke on “Emotional Issues in Prostate Cancer” and Thomas Kirk covered NASPCC’s exciting new Workplan resulting from two Strategic Planning Workshops held in April and May of this year in Los Angeles.
Two awards were presented, one for “Service to NASPCC”, and one for “Outstanding Prostate Cancer Coalition of 2017”. NASPCC President Merel Nissenberg of Los Angeles also received a Leadership Award from the organization.
NASPCC is a nation-wide not-for-profit organization comprised of state prostate cancer coalitions dedicated to saving men’s lives and enhancing the quality of life of prostate cancer patients and their families, through awareness and education and the development of a public policy network.
Next year’s 14th Annual Meeting of NASPCC is already being planned for October 12-14, 2018.
Read the Report of the 13th Annual Meeting - PDF
Download this Press Release below:
September is National Prostate Cancer Awareness Month.
One way to bring community awareness to this national event is by the issuance of a local government Proclamation.
Each year, the California Prostate Cancer Coalition (CPCC) produces two documents (see below) that volunteers can present to their local County Board of Supervisors and/or City Councils to request a Proclamation designating September as Prostate Cancer Awareness Month. Please feel free to use these for any city, county or Board of Supervisors in your respective states!
CPCC has done this Proclamations Project for the last 13 years spearheaded by our Board Member, Bill Doss.
The 13th Annual Meeting of NASPCC will be held in Washington, D.C.
October 13-15, 2017
NASPCC brings in one representative per state prostate cancer coalition for a weekend-long networking and educational event.
Other state representatives may attend as guests.
More info to follow!
The National Alliance of State Prostate Cancer Coalitions has joined with the United States Centers for Disease Control (CDC) and the University of Rochester to assist with the development of a dashboard intended to help men newly diagnosed with prostate cancer understand the pros and cons of different treatment options.
NASPCC’s role is to recruit newly diagnosed men to participate in one of three online studies to help evaluate the helpfulness of a decision making dashboard recently developed by the University of Rochester. Criteria for participants follows along with a link to the University of Rochester where those interested can register for the study:
We are looking for participants for three online studies:
- Low risk prostate cancer study - The study is open to men with newly diagnosed low risk prostate cancer. Participation in the study involves reviewing the decision tool you receive, answering a series of questions about how your treatment decision is made and how helpful you found the decision tool. You will also be asked to complete additional surveys about 3 and 9 months later that will inquire about how you are doing and how you feel about your choice of treatment. Everyone who participates will be entered into a lottery; winners will receive a $50 Amazon.com gift certificate.
- Intermediate risk prostate cancer study - The study is open to men with newly diagnosed intermediate risk prostate cancer. Participation in the study involves reviewing the decision tool you receive, answering a series of questions about how your treatment decision is made and how helpful you found the decision tool. You will also be asked to complete additional surveys about 3 and 9 months later that will inquire about how you are doing and how you feel about your choice of treatment. Everyone who participates will be entered into a lottery; winners will receive a $50 Amazon.com gift certificate.
- Prostate cancer survivor's study - We are looking for men with a history of prostate cancer willing to review the dashboard and give us feedback about what works, what doesn’t work, and how the dashboard can be improved. The study is also open to spouses, partners and other immediate family members of men with a history of prostate cancer. Participation in the study involves reviewing the decision dashboard and filling out a brief questionnaire.
Following is contact information for those interested in finding more about or joining the study: web - MCDM-MED.COM; call - (585) 275-5973; or email - This email address is being protected from spambots. You need JavaScript enabled to view it.
----
Photo credit: Image licensed through Creative Commons by Public Domain Pictures, Inc.